Comparing clinical trial data against a real world dataset – progression-free survival on Len/Dex and Bor/Dex following 1-3 prior lines of treatmentJ. Waters, Matthew Streetly, Sophie Deppe et al.|Clinical Lymphoma Myeloma & Leukemia|2019Cited by 1
P-393 A real-world UK experience of Daratumumab, Velcade, Dexamethasone and Carfilzomib, Lenalidomide, Dexamethasone as second line therapies in the UK: a South East London retrospectiveDogan Yildiz, Arief Gunawan, Sanela Kahrimanovic et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 0